Regional Differences in the Response of Human Pre-Adipocytes to PPARγ and RXRα Agonists
2002
We have previously reported that omental (OM) preadipocytes respond less well to the prodifferentiating effects of thiazolidinediones than do preadipocytes from subcutaneous (SC) depots. This finding is consistent with in vivo alterations in fat distribution that occur in humans treated with thiazolidinediones. To explore these site-related differences further, we used real-time RT-PCR to quantify the specific mRNAs encoding peroxisome proliferator-activated receptor (PPAR) γ1 and γ2 and found that both isoforms were more highly expressed in SC than in OM preadipocytes. After 10 days of thiazolidinedione treatment, preadipocytes from both depots showed a small and comparable increase in expression of PPARγ1 mRNA (1.7 ± 0.2-fold [ P = 0.007]) and 1.3 ± 0.1-fold [ P = 0.008] increase for SC and OM, respectively). There was a much larger increase in PPARγ2 expression, which was significantly greater in SC compared with OM preadipocytes (11.1 ± 2.8-fold [ P = 0.0003] and 5.5 ± 1.7-fold [ P = 0.0003], respectively; P = 0.014 for SC versus OM). To establish whether the refractoriness of OM preadipocytes to differentiation was unique to activators of the PPARγ pathway, we examined the effects of the retinoid X receptor (RXR) ligand LG100268. As assessed by glycerol-3-phosphate dehydrogenase activity, LG100268 had a greater effect on the differentiation of SC compared with OM preadipocytes when examined alone (SC = 5.7 ± 1.7-fold vs. OM = 1.9 ± 0.6-fold; P P
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
35
References
94
Citations
NaN
KQI